Company intelligence / Profile preview
Infusyn Therapeutics
Hackettstown, New Jersey, United Statesinfusyn.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Infusyn Therapeutics is developing precision dosing solutions using its Prometra II implantable infusion pump. The system is already approved and marketed for chronic pain and spasticity, while the company is advancing a proprietary drug/device program targeting pulmonary arterial hypertension toward an IND filing. No clinical results have been published yet for the PAH program, but commercial use exists in other indications.[1][2][3][4]
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- DeviceDrug/device combination therapySmall molecule (for drug candidates delivered via the device)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Algorithm SciencesLucius Partners/Lucius Venture Partners as key investor/advisorpotential future partnerships with companies developing similar drug/device programs
Beyond the preview
Go deeper on Infusyn Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infusyn Therapeutics.